

Preparation for use of Immune Globulin Intramuscular as Measles Post-Exposure Prophylaxis

Post-exposure prophylaxis (PEP) for measles, when provided within the target window, may provide measles protection, or modify the clinical course of disease among susceptible people. MMR vaccine or immunoglobulin can be given for PEP; additional information is available in the ACIP MMWR: <https://www.cdc.gov/mmwr/pdf/rr/rr6204.pdf>.

Immunoglobulin needs to be given within **6 days** of initial exposure and can be given intramuscularly (IGIM) or intravenously (IGIV).

GamaSTAN is the only available IGIM available in the U.S. GamaSTAN is supplied in 2mL and 10mL single dose vials. It is stored at 2-8°C (36-46°F) and has a shelf life of 3 years.

The CDC/ACIP IGIM recommended dose is **0.5mL/kg***; maximum dose by volume: 15mL.

*Note: CDC/ACIP recommended dosing different than the GamaSTAN package insert.

Package Insert available here: <https://www.fda.gov/media/86789/download?attachment>

Planning is critical to ensure rapid availability of IGIM after initial exposure.

To prepare for situations where IGIM may be needed for measles PEP, health departments can:

Before cases are identified

1. Establish a plan for obtaining IGIM, especially if there are areas with low MMR coverage. IGIM is not available through the Vaccines for Children (VFC) program. Contact your CDC Immunization Operations and Services Branch (IOSB) project officer for assistance if needed.
2. Work with **local hospitals or hospital systems** to identify available doses. IGIM does not require an infusion center or administration at a hospital, but local hospitals may have doses that could be used, if needed.
3. Health departments could also consider **acquiring doses directly** to use if needed for a measles exposure or outbreak.

Health departments could work through distribution partners to acquire IGIM.

Many states are members of [MMCAP Infuse](#); state and local health departments can purchase IGIM at a contracted rate through this national cooperative group. To get started with MMCAP Infuse, contacts by region are here: <https://infuse-mn.gov/products/product-ordering/index.jsp>.

After cases are identified

1. Work with **local hospitals** to identify doses that are immediately available. IGIM does not require an infusion center or administration at a hospital, but local hospitals may have doses that could be immediately accessible.
2. If local hospitals do not have sufficient doses and no other doses are available, contact MMCAP Infuse distributors or the manufacturer representative (manufacturer information here: <https://www.gamastan.com/en/hcp>).

Note for orders to be filled rapidly, an MMCAP account must already be established.